Graves病合并甲状腺眼病时甲亢的治疗
甲状腺眼病(TED)是Graves病(GD)最常见的甲状腺外表现或并发症。该综述检索截至2024年6月的指南、原始研究、临床试验、系统综述和Meta分析,探讨GD合并TED时甲亢的治疗选择。抗甲状腺药物(ATD)和甲状腺切除术不改变TED的自然病程,而放射性碘(RAI)与TED新发或进展/恶化的风险相关。
要点
- 轻度TED时任何甲亢治疗均可选用;若选RAI,对近期起病和/或有进展危险因素者强烈推荐短程低剂量泼尼松预防。
- 中重度活动性TED时ATD为首选,甲状腺切除术为有效选择;RAI一般避免,仅在临床需要时极谨慎使用。
- 中重度非活动性TED时三种甲亢治疗均可接受;RAI治疗者存在TED进展危险因素时应给予类固醇预防。
核心结论
- GD合并TED时甲亢治疗需根据TED的活动度与严重程度个体化选择,ATD和甲状腺切除术不改变TED自然病程,RAI与TED新发或进展/恶化风险相关。
研究设计与样本
- 综述检索截至2024年6月的现行指南、原始文章、临床试验、系统综述和Meta分析,检索词包括Graves病、Graves病管理、抗甲状腺药物、放射性碘、甲状腺切除术、甲状腺眼病、Graves眼眶病或眼病。
主要发现
- 抗甲状腺药物和甲状腺切除术不改变TED的自然病程,而放射性碘与TED新发或进展/恶化的少量但已充分记录的风险相关。
- 轻度TED时任何甲亢治疗均可使用;若选择RAI,对近期起病和/或存在进展危险因素者强烈推荐短程低剂量泼尼松预防。
- 中重度活动性TED时ATD为首选治疗,甲状腺切除术为有效选择;RAI一般避免,仅在临床需要时极谨慎使用,并需同时给予大剂量糖皮质激素(可联合或不联合眼眶放疗)积极治疗TED。
- 中重度非活动性TED时三种甲亢治疗均可接受,RAI治疗者识别出TED进展危险因素时应给予类固醇预防。
- 威胁视力的TED处理为绝对优先,甲亢应使用ATD控制直至TED得到控制。
关键数值与推荐
- 轻度TED且选择RAI时,若TED近期起病和/或存在进展危险因素,强烈推荐短程低剂量泼尼松预防。
- 中重度活动性TED时ATD为首选,甲状腺切除术为有效选择,RAI一般避免。
- 中重度非活动性TED时三种甲亢治疗均可接受,RAI治疗者存在TED进展危险因素时应给予类固醇预防。
- 威胁视力的TED为绝对优先,甲亢应使用ATD控制直至TED得到控制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves' disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression/worsening. In the presence of mild TED, any treatment for hyperthyroidism can be used, but should RAI treatment be selected, steroid prophylaxis (short course of low-dose prednisone) is strongly recommended if TED is of recent onset and/or risk factors for progression exist. In moderate to severe and active TED, ATDs are the preferred treatment, but thyroidectomy is a valid option. RAI ablation is generally avoided; it might be used when the clinical situation calls for it, but with extreme caution, if an aggressive treatment for TED with high-dose glucocorticoids (with or without orbital radiotherapy) is administered concomitantly. In moderate to severe and inactive TED, all 3 treatments for hyperthyroidism are acceptable, and steroid prophylaxis in RAI-treated patients should be given when risk factors for TED progression are identified. Management of sight-threatening TED represents the absolute priority, and hyperthyroidism should be controlled with ATDs until TED has been controlled. Search Strategies Current guidelines, original articles, clinical trials, systematic reviews, and meta-analyses up to June 2024 were searched using the following terms: "Graves' disease," "management of Graves' disease," "antithyroid drugs," "radioactive iodine," "thyroidectomy," "thyroid eye disease," "Graves' orbitopathy or ophthalmopathy."
引用
- Bartalena L, Smith TJ. Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease. J Clin Endocrinol Metab. 2025. PMID: 39787151. doi:10.1210/clinem/dgaf009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。